US FDA staff flag ‘serious’ safety risks for Intercept’s NASH treatment, Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com

The comments come ahead of the first meeting of the FDA’s outside advisers on Friday to discuss Intercept’s OCA for NASH, which has no approved therapies. The Food and Drug Administration’s reviewers flagged increased risk of diabetes and liver injury from using the oral tablets, called obeticholic acid (OCA), for the treatment of nonalcoholic steatohepatitis., The comments come ahead of the first meeting of the FDA’s outside advisers on Friday to discuss Intercept’s OCA for NASH, which has no approved therapies. The Food and Drug Administration’s reviewers flagged increased risk of diabetes and liver injury from using the oral tablets, called obeticholic acid (OCA), for the treatment of nonalcoholic steatohepatitis., , Read More